ATE538103T1 - Chinazolinonverbindungen als antikrebsmittel - Google Patents

Chinazolinonverbindungen als antikrebsmittel

Info

Publication number: ATE538103T1
Authority: AT; Austria
Prior art keywords: quinazolinone compounds; anticancer agents; quinazolinone; alone; compounds
Prior art date: 2003-11-25

Application number

AT04812051T

Other languages

English (en)

Inventor

Weibo Wang

Liana M Lagniton

Ryan N Constantine

Manoj C Desai

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-25

Filing date

2004-11-24

Publication date

2012-01-15

2004-11-24 Application filed by Novartis Ag filed Critical Novartis Ag

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538103T1 publication Critical patent/ATE538103T1/de

Links

AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title abstract 4
239000002246 antineoplastic agent Substances 0.000 title 1
239000003814 drug Substances 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04812051T 2003-11-25 2004-11-24 Chinazolinonverbindungen als antikrebsmittel ATE538103T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52505903P	2003-11-25	2003-11-25
PCT/US2004/039448 WO2005051922A1 (en)	2003-11-25	2004-11-24	Quinazolinone compounds as anticancer agents

Publications (1)

Publication Number	Publication Date
ATE538103T1 true ATE538103T1 (de)	2012-01-15

Family

ID=34632957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04812051T ATE538103T1 (de)	2003-11-25	2004-11-24	Chinazolinonverbindungen als antikrebsmittel

Country Status (17)

Country	Link
US (2)	US7939539B2 (de)
EP (1)	EP1689724B1 (de)
JP (2)	JP4778439B2 (de)
KR (1)	KR20060127413A (de)
CN (1)	CN1886384A (de)
AT (1)	ATE538103T1 (de)
AU (1)	AU2004293464A1 (de)
CA (1)	CA2546932A1 (de)
CY (1)	CY1112478T1 (de)
DK (1)	DK1689724T3 (de)
ES (1)	ES2376552T3 (de)
IL (1)	IL175714A0 (de)
PL (1)	PL1689724T3 (de)
PT (1)	PT1689724E (de)
SG (1)	SG148202A1 (de)
SI (1)	SI1689724T1 (de)
WO (1)	WO2005051922A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6545004B1 (en) *	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US7230000B1 (en) *	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US7671200B2 (en) *	1999-10-27	2010-03-02	Cytokinetics, Inc.	Quinazolinone KSP inhibitors
WO2003070701A2 (en) *	2002-02-15	2003-08-28	Cytokinetics, Inc.	Syntheses of quinazolinones
AU2003270015A1 (en) *	2002-05-09	2003-12-02	Cytokinetics, Inc.	Compounds, compositions, and methods
JP2005536475A (ja)	2002-05-23	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物、および方法
EP1537089A4 (de)	2002-07-23	2008-04-16	Cytokinetics Inc	Verbindungen, zusammenstellungen und verfahren
EP1558083A4 (de) *	2002-09-30	2008-04-16	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren
MXPA06011236A (es)	2004-04-02	2007-01-16	Prana Biotechnology Ltd	Compuestos neurologicamente activos.
BRPI0514390A (pt)	2004-08-18	2008-06-10	Astrazeneca Ab	enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
EP1786265A4 (de) *	2004-08-30	2009-08-19	Smithkline Beecham Corp	Neue zusammensetzungen und behandlungsverfahren
AU2005336092B2 (en) *	2004-09-14	2010-05-27	Cynthia C. Bamdad	Methods for diagnosis and treatment of cancer
US8754107B2 (en) *	2006-11-17	2014-06-17	Abbvie Inc.	Aminopyrrolidines as chemokine receptor antagonists
KR100916160B1 (ko) *	2007-02-21	2009-09-08	(주)바이오버드	약제학적 항암 조성물
AU2009215073A1 (en) *	2008-02-14	2009-08-20	Merck Sharp & Dohme Corp.	Inhibitors of checkpoint kinases
CN101250189B (zh) *	2008-03-25	2010-06-16	中山大学	双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CN101857595B (zh) *	2010-05-21	2012-11-21	中山大学	一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101899009B (zh) *	2010-07-30	2012-04-04	江苏昊华精细化工有限公司	医药中间体4(h)喹唑酮的制造方法
CN101967127B (zh) *	2010-09-28	2013-05-29	中山大学	一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
DE102012101680A1 (de) *	2012-02-29	2013-08-29	Aicuris Gmbh & Co. Kg	Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN104321325B (zh)	2012-05-24	2016-11-16	诺华股份有限公司	吡咯并吡咯烷酮化合物
CN103012291B (zh) *	2012-12-17	2014-09-03	中山大学	一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用
EP2935246B1 (de)	2012-12-21	2018-07-25	Gilead Calistoga LLC	Isochinolinon- oder chinazolinon-phosphatidylinositol-3-kinasehemmer
EP2941426B1 (de) *	2012-12-21	2018-06-13	Gilead Calistoga LLC	Substituierte pyrimidin-aminoalkyl-chinazolone als phosphatidylinositol-3-kinase-hemmer
WO2014115077A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Substituted purinone compounds
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CN105209467B (zh)	2013-05-27	2018-06-08	诺华股份有限公司	咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
ES2656471T3 (es)	2013-05-28	2018-02-27	Novartis Ag	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades
ES2650562T3 (es)	2013-05-28	2018-01-19	Novartis Ag	Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
TWI644909B (zh)	2013-06-14	2018-12-21	基利科學股份有限公司	磷脂酸肌醇３－激酶抑制劑
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9550796B2 (en)	2013-11-21	2017-01-24	Novartis Ag	Pyrrolopyrrolone derivatives and their use as BET inhibitors
CN106163568B (zh)	2013-12-23	2021-03-23	拜耳制药股份公司	含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
EP4066834A1 (de)	2014-03-19	2022-10-05	Infinity Pharmaceuticals, Inc.	Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen
WO2016020791A1 (en)	2014-08-05	2016-02-11	Novartis Ag	Ckit antibody drug conjugates
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN107635586B (zh)	2014-12-15	2021-09-24	拜耳医药股份有限公司	Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
EP3310440A1 (de)	2015-06-22	2018-04-25	Bayer Pharma Aktiengesellschaft	Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
WO2016207094A1 (de)	2015-06-23	2016-12-29	Bayer Pharma Aktiengesellschaft	Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2016207104A1 (de)	2015-06-23	2016-12-29	Bayer Pharma Aktiengesellschaft	Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
EP3317277B1 (de)	2015-07-01	2021-01-20	Crinetics Pharmaceuticals, Inc.	Somatostatinmodulatoren und verwendungen davon
CN108349985A (zh)	2015-09-14	2018-07-31	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP7022707B2 (ja)	2016-06-15	2022-02-18	バイエル・ファルマ・アクティエンゲゼルシャフト	Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
PE20191235A1 (es)	2016-12-21	2019-09-11	Bayer Pharma AG	Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
EP3558387B1 (de)	2016-12-21	2021-10-20	Bayer Pharma Aktiengesellschaft	Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
WO2019023278A1 (en)	2017-07-25	2019-01-31	Crinetics Pharmaceuticals, Inc.	MODULATORS OF SOMATOSTATIN AND USES THEREOF
CA3103327A1 (en)	2018-06-18	2019-12-26	Bayer Aktiengesellschaft	Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
CN111499634B (zh) *	2019-01-31	2023-05-12	贝达药业股份有限公司	一种喹唑啉化合物及其在医药上的应用
KR102622152B1 (ko)	2019-10-31	2024-01-08	홀로스메딕 주식회사	신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
KR102682775B1 (ko)	2020-06-26	2024-07-08	홀로스메딕 주식회사	신규한 화합물의 제조방법
WO2022231377A1 (ko)	2021-04-29	2022-11-03	홀로스메딕 주식회사	신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 및 그의 용도
KR102862736B1 (ko) *	2022-12-07	2025-09-22	부산대학교 산학협력단	신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4329418A1 (de) *	1993-09-01	1995-03-02	Agfa Gevaert Ag	Gelbkuppler
BR0015110A (pt) *	1999-10-27	2002-07-02	Cytokinetics Inc	Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
JP2002296741A (ja)	2001-03-30	2002-10-09	Fuji Photo Film Co Ltd	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
US6677110B2 (en) *	2001-03-30	2004-01-13	Fuji Photo Film Co., Ltd.	Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
JP4267838B2 (ja)	2001-03-30	2009-05-27	富士フイルム株式会社	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2002318442A (ja)	2001-04-20	2002-10-31	Fuji Photo Film Co Ltd	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP4267840B2 (ja)	2001-04-20	2009-05-27	富士フイルム株式会社	色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
EP1444209A4 (de)	2001-11-07	2005-02-16	Merck & Co Inc	Inhibitoren mitotischer kinesine
ATE372341T1 (de) *	2001-12-06	2007-09-15	Merck & Co Inc	Inhibitoren von mitotischem kinesin
AU2003270015A1 (en)	2002-05-09	2003-12-02	Cytokinetics, Inc.	Compounds, compositions, and methods
JP2006506401A (ja)	2002-05-23	2006-02-23	メルク　エンド　カムパニー　インコーポレーテッド	有糸分裂キネシン阻害薬
JP2005536475A (ja)	2002-05-23	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物、および方法
AU2003262747A1 (en)	2002-08-21	2004-03-11	Cytokinetics, Inc.	Compounds, compositions, and methods
EP1558083A4 (de)	2002-09-30	2008-04-16	Cytokinetics Inc	Verbindungen, zusammensetzungen und verfahren

2004
- 2004-11-24 PL PL04812051T patent/PL1689724T3/pl unknown
- 2004-11-24 SG SG200808730-6A patent/SG148202A1/en unknown
- 2004-11-24 US US10/996,814 patent/US7939539B2/en not_active Expired - Fee Related
- 2004-11-24 ES ES04812051T patent/ES2376552T3/es not_active Expired - Lifetime
- 2004-11-24 KR KR1020067012603A patent/KR20060127413A/ko not_active Withdrawn
- 2004-11-24 AT AT04812051T patent/ATE538103T1/de active
- 2004-11-24 CA CA002546932A patent/CA2546932A1/en not_active Abandoned
- 2004-11-24 SI SI200431833T patent/SI1689724T1/sl unknown
- 2004-11-24 EP EP04812051A patent/EP1689724B1/de not_active Expired - Lifetime
- 2004-11-24 CN CNA2004800348103A patent/CN1886384A/zh active Pending
- 2004-11-24 PT PT04812051T patent/PT1689724E/pt unknown
- 2004-11-24 JP JP2006541684A patent/JP4778439B2/ja not_active Expired - Fee Related
- 2004-11-24 WO PCT/US2004/039448 patent/WO2005051922A1/en not_active Ceased
- 2004-11-24 AU AU2004293464A patent/AU2004293464A1/en not_active Abandoned
- 2004-11-24 DK DK04812051.3T patent/DK1689724T3/da active
2006
- 2006-05-17 IL IL175714A patent/IL175714A0/en unknown
2010
- 2010-12-21 JP JP2010285141A patent/JP2011084570A/ja not_active Withdrawn
2011
- 2011-04-12 US US13/085,048 patent/US20110190293A1/en not_active Abandoned
2012
- 2012-03-12 CY CY20121100255T patent/CY1112478T1/el unknown

Also Published As

Publication number	Publication date
EP1689724B1 (de)	2011-12-21
DK1689724T3 (da)	2012-02-27
US7939539B2 (en)	2011-05-10
JP2011084570A (ja)	2011-04-28
WO2005051922A1 (en)	2005-06-09
CA2546932A1 (en)	2005-06-09
CY1112478T1 (el)	2015-12-09
SI1689724T1 (sl)	2012-04-30
CN1886384A (zh)	2006-12-27
PT1689724E (pt)	2012-02-06
AU2004293464A1 (en)	2005-06-09
IL175714A0 (en)	2006-09-05
EP1689724A1 (de)	2006-08-16
US20050209254A1 (en)	2005-09-22
JP2007512368A (ja)	2007-05-17
JP4778439B2 (ja)	2011-09-21
ES2376552T3 (es)	2012-03-14
SG148202A1 (en)	2008-12-31
PL1689724T3 (pl)	2012-05-31
US20110190293A1 (en)	2011-08-04
KR20060127413A (ko)	2006-12-12

Publication	Publication Date	Title
ATE538103T1 (de)	2012-01-15	Chinazolinonverbindungen als antikrebsmittel
WO2005070930A3 (en)	2006-01-19	Tetrahydrocarboline compounds as anticancer agents
TW200505454A (en)	2005-02-16	Heteroaryl-fused pyrimidinyl compounds as anticancer agents
DE602004025698D1 (de)	2010-04-08	PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
WO2004006859A3 (en)	2004-07-01	Platinum compound
TW200718689A (en)	2007-05-16	2-Amino-quinazolin-5-ones
BG108269A (en)	2004-12-30	Pyrazolopyrimidines as therapeutic agents
TW200716157A (en)	2007-05-01	Pharmaceutical formulations and methods of treatment using the same
TNSN08143A1 (en)	2009-07-14	2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
IL176110A0 (en)	2006-10-05	Azabicyclic heterocycles as cannabinoid receptor modulators
BG108268A (en)	2005-04-30	Pyrazolopyrimidines as therapeutic agents
TW200631578A (en)	2006-09-16	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
BRPI0414082A (pt)	2006-10-24	formas de dosagem de liberação sustentada de ziprasidona
TW200726765A (en)	2007-07-16	Triazolopyridine cannabinoid receptor 1 antagonists
MX2009003157A (es)	2009-04-03	Pirazoliltienopiridinas terapeuticas.
GT200900283A (es)	2011-10-05	"terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR052774A1 (es)	2007-04-04	Inmunoterapia para trastornos autoinmunes
WO2005004808A3 (en)	2005-03-17	TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
WO2007062093A3 (en)	2008-10-23	Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
EP1503748A4 (de)	2009-10-21	Arzneimittel zur linderung durch taxan induzierte neurotoxizität
TW200716091A (en)	2007-05-01	New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2008008556A (es)	2008-09-26	Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
MX2021011289A (es)	2021-11-03	Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.